Cantor Fitzgerald downgraded Akebia Therapeutics (NASDAQ:AKBA) to “neutral” from “overweight” and slashed its price target to $1 from $6 after the company received a complete response letter in response to the NDA for...
Cantor Fitzgerald launched coverage of Akebia Therapeutics (NASDAQ:AKBA) with an “overweight” rating and $8 price target. The stock closed at $3.41 on March 5. The company’s lead asset, vadadustat, is an oral hypoxia...
Analysts for BTIG and H.C. Wainwright reduced their price targets for Akebia Therapeutics (NASDAQ:AKBA) to $6 and $10, respectively, but maintained their “buy” ratings after the company announced top-line results for...
Akebia Therapeutics’ (NASDAQ:AKBA) vadadustat is being evaluated in an investigator-sponsored study as a potential therapy to prevent and lessen the severity of COVID-19-related acute respiratory distress syndrome...
Akebia Therapeutics (NASDAQ:AKBA) reported positive topline data from two Phase 3 studies of vadadustat for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis. The first study...
Akebia Therapeutics (NASDAQ:AKBA) vadadustat met its primary endpoint in two pivotal Phase 3 clinical trials for anemia due to chronic kidney disease (CKD). The trials compared the safety and efficacy of vadadustat to...